Furthermore, although the tau pathology to evolve to full-blown Alzheimer’s disease requires the concomitant presence of Aβ pathology (Braak and Del Tredici, 2011; Duyckaerts, 2011; Jack et al., 2013; Crary et al., 2014), the failure of anti-Aβ therapies in preventing the disease progression suggests that Alzheimer’s disease pathogenesis might be driven by tau independently of Aβ (Giacobini and Gold, 2013). Here, MAPT is linked to Alzheimer disease.